Placebo News and Research

RSS

$Zoledronate at lower dose effective in reducing risk of osteoporotic fractures$

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds.

7 Jun 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

7 Jun 2011

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

Sound Pharmaceuticals (SPI) will begin recruiting a new clinical trial testing the oral drug SPI-1005 to prevent the hearing loss induced by loud music. Exposure to loud music or noise can induce temporary and permanent auditory threshold shifts (TTS or PTS). In some people, a repeated TTS will ultimately give way to a PTS that is irreversible.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Female cancer survivors benefit from natural nutritional supplement

A natural nutritional supplement, marketed for the last decade as a sexual aid, has been shown to significantly improve overall quality of life for female cancer survivors, according to researchers at Wake Forest Baptist Medical Center.

7 Jun 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Flaxseed of no use in menopausal hot flashes: Study

Flaxseed has been the latest agent that has been tried in treating menopausal hot flashes and it is seen that it does not reduce the incidence of the unpleasant symptoms.

7 Jun 2011

Dr. Reddy’s launches generic ARICEPT, EFFEXOR XR and FEMARA in the US

Dr. Reddy's Laboratories today announced that it has launched three products in the US market.

6 Jun 2011

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

6 Jun 2011

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Adolor Corporation today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC).

6 Jun 2011

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Aradigm Corporation today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).

6 Jun 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).

6 Jun 2011

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).

6 Jun 2011

Placebo News and Research

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Female cancer survivors benefit from natural nutritional supplement

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Flaxseed of no use in menopausal hot flashes: Study

Dr. Reddy’s launches generic ARICEPT, EFFEXOR XR and FEMARA in the US

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

FDA accepts Sunovion ciclesonide HFA nasal aerosol NDA for review

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News